Message from CEO
"We provide services and products for the health of people and customers of the global healthcare industry with the best quality and safety."
Bushu Pharma has been operating as a dedicated CDMO since January 1999, meaning we are now in our 24th year of operation. During this time, thanks to the transfer of manufacturing technology and production of clinical trial supplies, pharmaceuticals, and medical devices consigned by our many customers, we have not only expanded our human resources but have also had the opportunity to accumulate a wide range of business experience. Offering improved manufacturing technology and product quality assurance levels, meeting deadlines, and becoming more cost competitive, we have grown – and continue to grow – to become a contract manufacturer specializing in pharmaceutical contract manufacturing.
We have obtained GMP certification not only in Japan, the U.S., and Europe, but also in many other countries, including Southeast Asia, Latin America, the Middle East, Africa, Canada, and Australia, in order to support the global market. We would like to take this opportunity to thank all of our contractors, business partners, and related supervisory agencies for their support.
In order to meet the rapidly increasing demand for outsourced manufacturing of injectable drug products, etc., Bushu Pharma began operating the Misato Cold Chain Center, a refrigerated warehouse with a rack structure and vibration reduction system, at the Misato Factory in September 2020. The company furthermore opened the Kazo Packaging Center, which also features refrigerated warehousing, in September 2021.
In December 2021, we started the "Gateway to Asia" project to import bulk products from international biopharmaceutical companies, conduct quality inspections, perform secondary packaging, and supply the products to Asian countries. We are also considering geographical expansion from Asia to Oceania and the Middle East, as well as the addition of production facilities. In January 2021, we started operation of high potency primary and secondary packaging lines in the Solid Dosage Form Area within the Misato Factory.
Most recently, in March 2022, we signed a basic agreement for the transfer of FUKUSHIMA Factory of Sanwa Kagaku Kenkyusho, a subsidiary of Suzuken. This has enabled us to establish a system of four production bases, further allowing us to meet the increasing demands of our customers.
In addition, we have been contracted to manufacture vaccines and therapeutics for new coronavirus (COVID-19) infections since 2020, and by manufacturing and supplying them in a timely manner, we are playing a part in solving an important social issue. We will continue to make every effort to solve various social issues, as represented and expressed by the SDGs.
As expressed above, in order to continue our growth, Bushu Pharma is enhancing its technological and corporate strengths by integrating a diverse group of people. In order for the company to work as one to make further progress, we have declared five promises (listed separately) as our mission statement in order to realize our corporate philosophy (mission) – "For the development of the global healthcare industry and human health”. We will steadily carry out these five promises, and all of our employees will work together to further refine our quality, stable supply, flexibility, speed, cost technology, and corporate culture. We will do our best to be recognized as your true partner.
We look forward to working with you in the future.
Chief Executive Officer / Executive Chairman